Medtronic plc (NYSE: MDT)

Medtronic plc, known by its ticker symbol MDT, is a prominent player in the global healthcare technology industry. Established in 1949 and headquartered in Dublin, Ireland, Medtronic is dedicated to enhancing human welfare through the application of biomedical engineering in the research, design, manufacture, and sale of products that alleviate pain, restore health, and extend life.

Medtronic's operations span across four reportable segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The company's products and therapies cater to healthcare systems, physicians' offices, ambulatory care centers, and other alternate site healthcare providers in over 150 countries worldwide.

The Cardiovascular Portfolio offers products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. This segment includes implantable devices, leads, and delivery systems, as well as remote monitoring services and patient-centered software. Medtronic's cardiac rhythm management devices, such as pacemakers and implantable cardioverter-defibrillators (ICDs), are renowned brand names under this portfolio.

The Neuroscience Portfolio provides solutions for the diagnosis, treatment, and management of neurological disorders, including stroke, Parkinson's disease, and epilepsy. The division's offerings include implantable devices, leads, and delivery systems, along with remote monitoring services and patient-centered software. Medtronic's deep brain stimulation (DBS) systems for the treatment of Parkinson's disease and essential tremor are notable brand names in this portfolio.

The Medical Surgical Portfolio comprises products for the diagnosis, treatment, and management of surgical and endoscopic procedures. The division's product range includes advanced stapling devices, vessel sealing instruments, wound closure products, electrosurgery products, and robotic-assisted surgery products. Medtronic's surgical stapling and cutting devices are well-known brand names under this portfolio.

The Diabetes Operating Unit offers products for the management of Type 1 and Type 2 diabetes. The division's product offerings include insulin pumps and consumables, continuous glucose monitoring systems, and smart insulin pens. Medtronic's insulin pumps and continuous glucose monitoring systems are popular brand names in this portfolio.

Medtronic's workforce, numbering over 95,000 employees, is diverse and global, with 44% based in the United States or Puerto Rico. The company prioritizes creating an inclusive and diverse workplace, focusing on diversity, equity, and inclusion. Medtronic's culture is anchored in its core values of integrity, quality, inclusion, and collaboration, which encourage employees to act boldly, compete to win, move with speed and decisiveness, foster belonging, and deliver results the right way.

Medtronic's commitment to employee engagement and culture is demonstrated through its Organizational Health Survey, which provides valuable insights into the employee experience and helps identify areas for improvement. The company is dedicated to maintaining a safe workplace and supporting the well-being of its employees, offering comprehensive support for employees and their families during crises, such as natural disasters, public health crises, and bereavement.

Medtronic's products and therapies are subject to extensive regulation by numerous government agencies, including the U.S. Food and Drug Administration (FDA), European regulatory authorities, and other government agencies inside and outside the U.S. The company is also subject to trade regulations, anti-boycott laws, data privacy and security laws, regulations governing reimbursement, and environmental health and safety laws.